Skip to content
Subscriber Only

Teva Analysts Say Migraine Drug Approval Gives Needed Relief

  • Medicine is second FDA-approved product in its drug class
  • Has potential to be blockbuster with $1 billion in sales: BTIG
Bottles of Teva Pharmaceutical Industries Ltd. products.

Bottles of Teva Pharmaceutical Industries Ltd. products.

Photographer: George Frey/
Updated on

Teva Pharmaceutical Industries Ltd. climbed as much as 7.4 percent in early U.S. trading after FDA approval of its migraine drug, Ajovy, surprised the Street. The medicine is the second of its kind, behind Amgen’s Aimovig, and has the potential to reach sales of $1 billion in four years, according to BTIG analyst Timothy Chiang.

Read more about Teva’s turnaround here